Skip to main content
. 2023 Feb 9;20:15. doi: 10.1186/s12954-023-00743-8

Table 1.

Description and comparison of socio-demographics characteristics and of previous testing and treatment for HCV among respondents identified with current/former injection drug users compared to other respondents, N = 202

Other respondents n = 140 (69.3%) Respondents identified with current/former injection drug users n = 62 (30.7%) Total N = 202 p value
n (%) n (%) N (%)
Age median [IQR] (n = 189) 39 [31–51] 48 [36–57] 42 [33–52] 0.003
Gender (n = 200) 0.393
Male 76 (54.7) 37 (60.7) 113 (56.5)
Female 60 (43.2) 21 (34.4) 81 (40.5)
Transgender 1 (0.7) 1 (1.6) 2 (1.0)
Gender non-binary 2 (1.4) 2 (3.3) 4 (2.0)
Living area (n = 199) 0.022
Urban area/large city/Near a large city 93 (67.4) 44 (72.1) 137 (68.8)
Semi-urban area/small or medium city 33 (23.9) 6 (9.8) 39 (19.6)
Rural area/Village 12 (8.7) 11 (18.0) 23 (11.6)
Highest level of education completed (n = 198) 0.379
Never went to school/primary/secondary (middle school/high school) 15 (10.8) 9 (15.3) 24 (12.1)
Tertiary (college, university, or vocational training) 124 (89.2) 50 (84.7) 174 (87.9)
Previously tested for HCV (n = 201) 0.001
Yes 90 (64.3) 55 (90.2) 145 (72.1)
No/I do not know 50 (35.7) 6 (9.8) 56 (27.9)
Previously tested positive for HCV (n = 139)a  < 0.001
Yes 19 (22.6) 38 (69.1) 57 (41.0)
No 65 (77.4) 17 (30.9) 82 (59.0)
Previously tested positive with RNA PCR for HCV (n = 57)b NA
Yes 18 (94.7) 36 (94.7) 54 (94.7)
No/I do not know 1 (5.3) 2 (5.3) 3 (5.3)
Previous treatment for HCV (n = 53)c 0.153
Yes 18 (100.0) 30 (85.7) 48 (90.6)
No 0 (0.0) 5 (14.3) 5 (9.4)

Missing values were excluded of this comparison/P-values in bold are significant

aAmong those previously tested for HCV

bAmong those previously tested positive for HCV

cAmong those previously tested positive with RNA HCV for HCV